Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Gene Therapy
  4. Volume 25, Issue 1
  5. Article
Volume 25, Issue 1
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

Background

Metastatic Triple-negative Breast Cancer (mTNBC) is the most aggressive form of breast cancer, with a greater risk of metastasis and recurrence. Research studies have published in-depth analyses of the advantages and disadvantages of pembrolizumab, and early data from numerous trials suggests that patients with mTNBC have had remarkable outcomes. This meta-analysis compares the data from numerous relevant studies in order to evaluate the safety and efficacy of pembrolizumab monotherapy or combination therapies for mTNBC.

Methods

To identify eligible RCTs, a thorough literature search was carried out using electronic databases. CMA software was utilized to perform heterogeneity tests using fixed and random-effects models.

Results

According to our pooled data, the median Progression-free Survival (PFS) was 2.66 months, and the median overall survival (OS) was 12.26 months. Furthermore, by comparing efficacy indicators between PD-L1–positive and PD-L1–negative groups, a correlation was found between the overexpression of PD-L1 with OS, PFS, and ORR. Patients with PD-L1-positive tumors had a higher response rate, with an ORR of 21.1%, compared to the patients with PD-L1-negative tumors. The ORR for first-line immunotherapy was higher than that of ≥second-line immunotherapy. In addition, pembrolizumab plus combination treatment resulted in a pooled incidence of immune-related adverse events of 22.7%.

Conclusion

A modest response to pembrolizumab monotherapy was detected in the mTNBC patients. Furthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1-positive status, non-liver/lung metastases, combination therapy, and first-line immunotherapy. Pembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors are PD-L1 positive.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cgt/10.2174/0115665232283880240301035621
2025-02-01
2025-01-19

  • From This Site

    /content/journals/cgt/10.2174/0115665232283880240301035621
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. YinL. DuanJ.J. BianX.W. YuS. Triple-negative breast cancer molecular subtyping and treatment progress.Breast Cancer Res.20202216110.1186/s13058‑020‑01296‑532517735
     [Google Scholar]
  2. KenneckeH. YerushalmiR. WoodsR. CheangM.C.U. VoducD. SpeersC.H. NielsenT.O. GelmonK. Metastatic behavior of breast cancer subtypes.J. Clin. Oncol.201028203271327710.1200/JCO.2009.25.982020498394
     [Google Scholar]
  3. AlimohammadiM. RahimiA. FaramarziF. GolpourM. ShakibJ.R. NavaeiA.R. RafieiA. Effects of coenzyme Q10 supplementation on inflammation, angiogenesis, and oxidative stress in breast cancer patients: A systematic review and meta-analysis of randomized controlled- trials.Inflammopharmacology202129357959310.1007/s10787‑021‑00817‑834008150
     [Google Scholar]
  4. MillerK.D. NogueiraL. MariottoA.B. RowlandJ.H. YabroffK.R. AlfanoC.M. JemalA. KramerJ.L. SiegelR.L. Cancer treatment and survivorship statistics, 2019.CA Cancer J. Clin.201969536338510.3322/caac.2156531184787
     [Google Scholar]
  5. AndersC.K. AbramsonV. TanT. DentR. The evolution of triple-negative breast cancer: From biology to novel therapeutics.Am. Soc. Clin. Oncol. Educ. Book20163536344210.1200/EDBK_15913527249684
     [Google Scholar]
  6. WangX. QiY. KongX. ZhaiJ. LiY. SongY. WangJ. FengX. FangY. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.Cancer Lett.201944240942810.1016/j.canlet.2018.10.04230419345
     [Google Scholar]
  7. RenY. SongJ. LiX. LuoN. Rationale and clinical research progress on PD-1/PD-L1-based immunotherapy for metastatic triple-negative breast cancer.Int. J. Mol. Sci.20222316887810.3390/ijms2316887836012144
     [Google Scholar]
  8. QiY. ZhangL. WangZ. KongX. ZhaiJ. FangY. WangJ. Efficacy and safety of Anti-PD-1/ PD-L1 monotherapy for metastatic breast cancer: Clinical evidence.Front. Pharmacol.20211265352110.3389/fphar.2021.65352134267656
     [Google Scholar]
  9. HowardF.M. PearsonA.T. NandaR. Clinical trials of immunotherapy in triple-negative breast cancer.Breast Cancer Res. Treat.2022195111510.1007/s10549‑022‑06665‑635834065
     [Google Scholar]
  10. AbdouY. GoudarziA. YuJ.X. UpadhayaS. VincentB. CareyL.A. Immunotherapy in triple negative breast cancer: Beyond checkpoint inhibitors. npj.Breast Cancer20228111035013314
     [Google Scholar]
  11. TwomeyJ.D. ZhangB. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics.AAPS J.20212323910.1208/s12248‑021‑00574‑033677681
     [Google Scholar]
  12. LarkinJ. SileniC.V. GonzalezR. GrobJ.J. CoweyC.L. LaoC.D. SchadendorfD. DummerR. SmylieM. RutkowskiP. FerrucciP.F. HillA. WagstaffJ. CarlinoM.S. HaanenJ.B. MaioM. RodasM.I. McArthurG.A. AsciertoP.A. LongG.V. CallahanM.K. PostowM.A. GrossmannK. SznolM. DrenoB. BastholtL. YangA. RollinL.M. HorakC. HodiF.S. WolchokJ.D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N. Engl. J. Med.20153731233410.1056/NEJMoa150403026027431
     [Google Scholar]
  13. LarkinsE. BlumenthalG.M. YuanW. HeK. SridharaR. SubramaniamS. ZhaoH. LiuC. YuJ. GoldbergK.B. McKeeA.E. KeeganP. PazdurR. FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy.Oncologist201722787387810.1634/theoncologist.2016‑049628533473
     [Google Scholar]
  14. RobertC. LongG.V. BradyB. DutriauxC. MaioM. MortierL. HasselJ.C. RutkowskiP. McNeilC. WarzochaK.E. SavageK.J. HernbergM.M. LebbéC. CharlesJ. MihalcioiuC. SileniC.V. MauchC. CognettiF. AranceA. SchmidtH. SchadendorfD. GogasH. ErikssonL.L. HorakC. SharkeyB. WaxmanI.M. AtkinsonV. AsciertoP.A. Nivolumab in previously untreated melanoma without BRAF mutation.N. Engl. J. Med.2015372432033010.1056/NEJMoa141208225399552
     [Google Scholar]
  15. TopalianS.L. HodiF.S. BrahmerJ.R. GettingerS.N. SmithD.C. McDermottD.F. PowderlyJ.D. CarvajalR.D. SosmanJ.A. AtkinsM.B. LemingP.D. SpigelD.R. AntoniaS.J. HornL. DrakeC.G. PardollD.M. ChenL. SharfmanW.H. AndersR.A. TaubeJ.M. McMillerT.L. XuH. KormanA.J. Jure-KunkelM. AgrawalS. McDonaldD. KolliaG.D. GuptaA. WiggintonJ.M. SznolM. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N. Engl. J. Med.2012366262443245410.1056/NEJMoa120069022658127
     [Google Scholar]
  16. TopalianS.L. SznolM. McDermottD.F. KlugerH.M. CarvajalR.D. SharfmanW.H. BrahmerJ.R. LawrenceD.P. AtkinsM.B. PowderlyJ.D. LemingP.D. LipsonE.J. PuzanovI. SmithD.C. TaubeJ.M. WiggintonJ.M. KolliaG.D. GuptaA. PardollD.M. SosmanJ.A. HodiF.S. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J. Clin. Oncol.201432101020103010.1200/JCO.2013.53.010524590637
     [Google Scholar]
  17. RizzoA. RicciA.D. LanotteL. LombardiL. FedericoD.A. BrandiG. CaldarolaG.G. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: Current knowledge and therapeutic prospects.Expert Opin. Investig. Drugs202231655756510.1080/13543784.2022.200945634802383
     [Google Scholar]
  18. HuppertL.A. GumusayO. RugoH.S. Emerging treatment strategies for metastatic triple-negative breast cancer.Ther. Adv. Med. Oncol.202214.10.1177/1758835922108691635422881
     [Google Scholar]
  19. AlimohammadiM. FaramarziF. MafiA. MousaviT. RahimiA. MirzaeiH. AsemiZ. Efficacy and safety of atezolizumab monotherapy or combined therapy with chemotherapy in patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials.Curr. Pharm. Des.202329312461247610.2174/011381612827010223101611063737921135
     [Google Scholar]
  20. DemariaS. GoldenE.B. FormentiS.C. Role of local radiation therapy in cancer immunotherapy.JAMA Oncol.2015191325133210.1001/jamaoncol.2015.275626270858
     [Google Scholar]
  21. FukumuraD. KloepperJ. AmoozgarZ. DudaD.G. JainR.K. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges.Nat. Rev. Clin. Oncol.201815532534010.1038/nrclinonc.2018.2929508855
     [Google Scholar]
  22. PfirschkeC. EngblomC. RickeltS. Cortez-RetamozoV. GarrisC. PucciF. YamazakiT. ColameP.V. NewtonA. RedouaneY. LinY.J. WojtkiewiczG. IwamotoY. Mino-KenudsonM. HuynhT.G. HynesR.O. FreemanG.J. KroemerG. ZitvogelL. WeisslederR. PittetM.J. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy.Immunity201644234335410.1016/j.immuni.2015.11.02426872698
     [Google Scholar]
  23. LuoC. WangP. HeS. ZhuJ. ShiY. WangJ. Progress and prospect of immunotherapy for triple-negative breast cancer.Front. Oncol.20221291907210.3389/fonc.2022.91907235795050
     [Google Scholar]
  24. UlianoJ NicolòE CorvajaC SalimbeniT.B TrapaniD CuriglianoG. Combination immunotherapy strategies for triple-negative breast cancer: Current progress and barriers within the pharmacological landscape.Expert Rev Clin Pharmacol202215121399141310.1080/17512433.2022.2142559
     [Google Scholar]
  25. HodiF.S. ChesneyJ. PavlickA.C. RobertC. GrossmannK.F. McDermottD.F. LinetteG.P. MeyerN. GiguereJ.K. AgarwalaS.S. ShaheenM. ErnstoffM.S. MinorD.R. SalamaA.K. TaylorM.H. OttP.A. HorakC. GagnierP. JiangJ. WolchokJ.D. PostowM.A. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Lancet Oncol.201617111558156810.1016/S1470‑2045(16)30366‑727622997
     [Google Scholar]
  26. GandhiL. AbreuR.D. GadgeelS. EstebanE. FelipE. De AngelisF. DomineM. ClinganP. HochmairM.J. PowellS.F. ChengS.Y.S. BischoffH.G. PeledN. GrossiF. JennensR.R. ReckM. HuiR. GaronE.B. BoyerM. ViqueiraR.B. NovelloS. KurataT. GrayJ.E. VidaJ. WeiZ. YangJ. RaftopoulosH. PietanzaM.C. GarassinoM.C. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer.N. Engl. J. Med.2018378222078209210.1056/NEJMoa180100529658856
     [Google Scholar]
  27. CortesJ. CesconD.W. RugoH.S. NoweckiZ. ImS.A. YusofM.M. GallardoC. LipatovO. BarriosC.H. HolgadoE. IwataH. MasudaN. OteroM.T. GokmenE. LoiS. GuoZ. ZhaoJ. AktanG. KarantzaV. SchmidP. LuisF. GonzaloG.A. DiegoK. RubenK. MatiasM. MirtaV. SallyB-H. StephenB. PhilipC. ShereneL. DhanushaS. AndreaG. DonatienneT. CarlosB. LeandroB. FabianoC. RuffoF.J. RobertoH. CarvalhoD.L. ToniazziF.C.L. OdebrechtR.R. OrlandoA.S.N. FelipeS. DavidC. DanielleC. CristianoF. XinniS. JoanneY. AlejandroA. CarlosG. ClaudioS. CesarS. EduardoY. AlvaroG.D. JesusS. PetraH. ZdenekK. BohuslavM. KatarinaP. JanaP. VesnaG. ErikJ. JeanetteJ. SorenL. TamasL. HerveB. IsabelleD. AnthonyG. Anne-ClaireH-B. LuisT. Jens-UweB. PeterF. DirkF. NadiaH. JensH. AnnaK.F.S. ChristianK. SibylleL. DianaL. Tjoung-WonP-S. Raquel VonS. PaulineW. LouisC. AvaK. RogerK.C.N. PeterA. TiborC. ZsuzsannaK. LaszloL. KarolyM. GaborR. JohnC. CatherineK. SeamusO.R. SaverioC. AntoniettaD.A. EnricoR. TomoyukiA. TakaakiF. KenichiI. TakashiI. YoshinoriI. TsutomuI. HirojiI. YoshimasaK. KojiM. YasuoM. HirofumiM. SeigoN. NaokiN. ShoichiroO. AkihikoO. YasuakiS. EijiS. MasatoT. YukoT. KenjiT. KoichiroT. JunichiroW. NaohitoY. YutakaY. TeruoY. AnitaB. MasturaM.Y. AngelG.V. AlejandroJ.R. JorgeM.R. FlaviaM-V. JessicaR.C. KarinB. VivianneT-H. DavidP. EwaC. EwaN-Z. ZbigniewN. BarbaraR. JoannaS. CezaryS. RafalT. BogdanZ. AlexanderA. NataliaF. OlegL. AndreyM. VladimirM. GuzelM. Jin HeeA. Seock-AhI. Keun SeokL. Kwong HwaP. Yeon HeeP. BegonaB.H. JavierC. JosefinaC.J. LuisC.M. JoseG.S. MariaG. EstherH. EstherZ.A. Chien-TingL. Mei-ChingL. Chiun-ShengH. Chao-JungT. Ling-MingT. CagatayA. GulB. IrfanC. ErhanG. SeydaG. NilM.M. MustafaO. OzgurO. SinanY. SteveC. JanineG. IainM.P. PeterS. NicholasT. MarkT. ChristopherT. DuncanW. HryhoriyA. OleksandrB. IgorB. OleksiiK. OlenaK. HannaK. AnnaK. IuriiL. AllaN. NatalyaO. OlgaP. AndriiR. SergiiS. YaroslavS. DmytroT. GrygoriiU. IhorV. SibelB. MadhuC. MichaelC. PatrickC. ScottC. JenniferD. KeerthiG. JeffreyH. KentH. WilliamI. RandaL. JaniceL. RaulM. SusanM. RitaN. IraO. CoralO. TimothyP. AmitP. BrianP. HopeR. IrinaR. MichaelS. RobertS. MichaelS. LauraS. BradleyS. MichaelaT. FrancesV-A. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial.Lancet2020396102651817182810.1016/S0140‑6736(20)32531‑933278935
     [Google Scholar]
  28. SchmidP. SalgadoR. ParkY.H. Muñoz-CouseloE. KimS.B. SohnJ. ImS.A. FoukakisT. KuemmelS. DentR. YinL. WangA. TryfonidisK. KarantzaV. CortésJ. LoiS. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study.Ann. Oncol.202031556958110.1016/j.annonc.2020.01.07232278621
     [Google Scholar]
  29. CortésJ. LipatovO. ImS-A. GonçalvesA. LeeK.S. SchmidP. TamuraK. TestaL. WitzelI. OhtaniS. ZambelliS. HarbeckN. AndréF. DentR. ZhouX. KarantzaV. MejiaJ.A. WinerE.P. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC).Ann. Oncol.201930v859v86010.1093/annonc/mdz394.010
     [Google Scholar]
  30. ZouY. ZouX. ZhengS. TangH. ZhangL. LiuP. XieX. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: A systematic review and meta-analysis.Ther. Adv. Med. Oncol.202012175883592094092810.1177/175883592094092832874208
     [Google Scholar]
  31. SimmonsC.E. Brezden-MasleyC. McCarthyJ. McLeodD. JoyA.A. Positive progress: Current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer.Ther. Adv. Med. Oncol.202012175883592090909110.1177/175883592090909133014143
     [Google Scholar]
  32. AminM SharifS AsgharW SadafH SarfrazA SarfrazZ Atezolizumab and pembrolizumab in triple-negative breast cancer: A meta-analysis.Expert Rev Anticancer Ther202122222923510.20944/preprints202105.0546.v1
     [Google Scholar]
  33. BrahmerJ.R. LacchettiC. SchneiderB.J. AtkinsM.B. BrassilK.J. CaterinoJ.M. ChauI. ErnstoffM.S. GardnerJ.M. GinexP. HallmeyerS. ChakrabartyH.J. LeighlN.B. MammenJ.S. McDermottD.F. NaingA. NastoupilL.J. PhillipsT. PorterL.D. PuzanovI. ReichnerC.A. SantomassoB.D. SeigelC. SpiraA. AlmazorS.M.E. WangY. WeberJ.S. WolchokJ.D. ThompsonJ.A. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.J. Clin. Oncol.201836171714176810.1200/JCO.2017.77.638529442540
     [Google Scholar]
  34. PostowM.A. SidlowR. HellmannM.D. Immune-related adverse events associated with immune checkpoint blockade.N. Engl. J. Med.2018378215816810.1056/NEJMra170348129562154
     [Google Scholar]
  35. VinayakS. TolaneyS.M. SchwartzbergL. MitaM. McCannG. TanA.R. HendricksonW.A.E. ForeroA. AndersC. WulfG.M. DillonP. LynceF. ZarwanC. ErbanJ.K. ZhouY. BuerstatteN. GrahamJ.R. AroraS. DezubeB.J. TelliM.L. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.JAMA Oncol.2019581132114010.1001/jamaoncol.2019.102931194225
     [Google Scholar]
  36. LiberatiA. AltmanD.G. TetzlaffJ. MulrowC. GøtzscheP.C. IoannidisJ.P.A. ClarkeM. DevereauxP.J. KleijnenJ. MoherD. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration.BMJ2009339b270010.1136/bmj.b270019622552
     [Google Scholar]
  37. HigginsJ.P.T. AltmanD.G. GøtzscheP.C. JüniP. MoherD. OxmanA.D. SavovicJ. SchulzK.F. WeeksL. SterneJ.A.C. The cochrane collaboration’s tool for assessing risk of bias in randomised trials.BMJ2011343oct18 2d592810.1136/bmj.d592822008217
     [Google Scholar]
  38. AlimohammadiM. RahimiA. FaramarziF. NavaeiA.R. RafieiA. Overexpression of chemokine receptor CXCR4 predicts lymph node metastatic risk in patients with melanoma: A systematic review and meta-analysis.Cytokine202114815569110.1016/j.cyto.2021.15569134464923
     [Google Scholar]
  39. McDermottD.F. AtkinsM.B. PD -1 as a potential target in cancer therapy.Cancer Med.20132566267310.1002/cam4.10624403232
     [Google Scholar]
  40. RizzoA. RicciA.D. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.Expert Opin. Investig. Drugs202231654955510.1080/13543784.2022.200835434793275
     [Google Scholar]
  41. KumarS. ChatterjeeM. GhoshP. GangulyK.K. BasuM. GhoshM.K. Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.Genes Dis.20231041318135010.1016/j.gendis.2022.07.02437397537
     [Google Scholar]
  42. NandaR. ChowL.Q.M. DeesE.C. BergerR. GuptaS. GevaR. PusztaiL. PathirajaK. AktanG. ChengJ.D. KarantzaV. BuisseretL. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study.J. Clin. Oncol.201634212460246710.1200/JCO.2015.64.893127138582
     [Google Scholar]
  43. NandaR SpechtJ DeesC BergerR GuptaS GevaR Abstract P6-10-03: KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC).Cancer Res.201777S4P6-10-03
     [Google Scholar]
  44. AdamsS. SchmidP. RugoH.S. WinerE.P. LoiratD. AwadaA. CesconD.W. IwataH. CamponeM. NandaR. HuiR. CuriglianoG. ToppmeyerD. O’ShaughnessyJ. LoiS. ShimonP.S. TanA.R. CardD. ZhaoJ. KarantzaV. CortésJ. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study.Ann. Oncol.201930339740410.1093/annonc/mdy51730475950
     [Google Scholar]
  45. AdamsS. LoiS. ToppmeyerD. CesconD.W. De LaurentiisM. NandaR. WinerE.P. MukaiH. TamuraK. ArmstrongA. LiuM.C. IwataH. RyvoL. WimbergerP. RugoH.S. TanA.R. JiaL. DingY. KarantzaV. SchmidP. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study.Ann. Oncol.201930340541110.1093/annonc/mdy51830475947
     [Google Scholar]
  46. SharmaP. LieskovanH.S. WargoJ.A. RibasA. Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017168470772310.1016/j.cell.2017.01.01728187290
     [Google Scholar]
  47. HuangM. FaschingP. HaideraliA. PanW. GrayE. ZhouZ.Y. HuP. ChaudhuriM. TilleghemB.D.C.L. CappoenN. O’ShaughnessyJ. Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.Immunotherapy202214131027104110.2217/imt‑2022‑008235796042
     [Google Scholar]
  48. BianchiniG. De AngelisC. LicataL. GianniL. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs.Nat. Rev. Clin. Oncol.20221929111310.1038/s41571‑021‑00565‑234754128
     [Google Scholar]
  49. RehmanM.U.U. AliI. ZiaH. Pembrolizumab and chemotherapy with radiology comparative analysis in patients with untreated metastatic triple negative breast cancer.Pak. J. Med. Health Sci.20221607796
     [Google Scholar]
  50. PaulsM. ChiaS. LeVasseurN. Current and new novel combination treatments for metastatic triple-negative breast cancer.Curr. Oncol.20222974748476710.3390/curroncol2907037735877237
     [Google Scholar]
  51. EmensL.A. MiddletonG. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies.Cancer Immunol. Res.20153543644310.1158/2326‑6066.CIR‑15‑006425941355
     [Google Scholar]
  52. WinerE.P. LipatovO. ImS.A. GoncalvesA. CouseloM.E. LeeK.S. SchmidP. TamuraK. TestaL. WitzelI. OhtaniS. TurnerN. ZambelliS. HarbeckN. AndreF. DentR. ZhouX. KarantzaV. MejiaJ. CortesJ. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial.Lancet Oncol.202122449951110.1016/S1470‑2045(20)30754‑333676601
     [Google Scholar]
  53. TolaneyS.M. KalinskyK. KaklamaniV.G. D’AdamoD.R. AktanG. TsaiM.L. O’ReganR.M. KaufmanP.A. WilksS.T. AndreopoulouE. PattD.A. YuanY. WangG. SavulskyC. XingD. KleynermanE. KarantzaV. DiabS. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase Ib/II study.Clin. Cancer Res.202127113061306810.1158/1078‑0432.CCR‑20‑472633727258
     [Google Scholar]
  54. YoungK.H. BairdJ.R. SavageT. CottamB. FriedmanD. BambinaS. MessenheimerD.J. FoxB. NewellP. BahjatK.S. GoughM.J. CrittendenM.R. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy.PLoS One2016116e015716410.1371/journal.pone.015716427281029
     [Google Scholar]
  55. DovediS.J. AdlardA.L. Lipowska-BhallaG. McKennaC. JonesS. CheadleE.J. StratfordI.J. PoonE. MorrowM. StewartR. JonesH. WilkinsonR.W. HoneychurchJ. IllidgeT.M. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.Cancer Res.201474195458546810.1158/0008‑5472.CAN‑14‑125825274032
     [Google Scholar]
  56. BuchwaldZ.S. WynneJ. NastiT.H. ZhuS. MouradW.F. YanW. GuptaS. KhleifS.N. KhanM.K. Radiation, immune checkpoint blockade and the abscopal effect: A critical review on timing, dose and fractionation.Front. Oncol.2018861210.3389/fonc.2018.0061230619752
     [Google Scholar]
  57. EstevaF.J. Hubbard-LuceyV.M. TangJ. PusztaiL. Immunotherapy and targeted therapy combinations in metastatic breast cancer.Lancet Oncol.2019203e175e18610.1016/S1470‑2045(19)30026‑930842061
     [Google Scholar]
  58. LukeJ.J. LemonsJ.M. KarrisonT.G. PitrodaS.P. MelotekJ.M. ZhaY. Al-HallaqH.A. ArinaA. KhodarevN.N. JanischL. ChangP. PatelJ.D. FlemingG.F. MoroneyJ. SharmaM.R. WhiteJ.R. RatainM.J. GajewskiT.F. WeichselbaumR.R. ChmuraS.J. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors.J. Clin. Oncol.201836161611161810.1200/JCO.2017.76.222929437535
     [Google Scholar]
  59. HoA.Y. BarkerC.A. ArnoldB.B. PowellS.N. HuZ.I. GucalpA. ZapataL.L. WenH.Y. KallmanC. D’AgnoloA. ZhangZ. FlynnJ. DunnS.A. McArthurH.L. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.Cancer2020126485086010.1002/cncr.3259931747077
     [Google Scholar]
  60. AdamsS. SchmidP. RugoH.S. WinerE.P. LoiratD. AwadaA. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.Clin. Oncol.2017351510.1200/JCO.2017.35.15_suppl.1008
     [Google Scholar]
  61. VinayakS. TolaneyS.M. SchwartzbergL.S. MitaM.M. McCannG.A-L. TanA.R. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.J. Clin. Oncol.201836151011
     [Google Scholar]
  62. QinG. WangX. YeS. LiY. ChenM. WangS. QinT. ZhangC. LiY. LongQ. HuH. ShiD. LiJ. ZhangK. ZhaiQ. TangY. KangT. LanP. XieF. LuJ. DengW. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.Nat. Commun.2020111166910.1038/s41467‑020‑15364‑z32245950
     [Google Scholar]
  63. Abdel-RahmanO. FouadM. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: A meta-analysis.Ther. Adv. Respir. Dis.201610318319310.1177/175346581663655726944362
     [Google Scholar]
  64. XuC. ChenY.P. DuX.J. LiuJ.Q. HuangC.L. ChenL. Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis.BMJ2018363k422610.1136/bmj.k4226
     [Google Scholar]
  65. WangY. ZhouS. YangF. QiX. WangX. GuanX. ShenC. DumaN. AguileraV.J. ChintakuntlawarA. PriceK.A. MolinaJ.R. PagliaroL.C. HalfdanarsonT.R. GrotheyA. MarkovicS.N. NowakowskiG.S. AnsellS.M. WangM.L. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis.JAMA Oncol.2019571008101910.1001/jamaoncol.2019.039331021376
     [Google Scholar]
  66. NaingA. Being realistic and optimistic in curing cancer.J. Immunother. Precis. Oncol.2018125355
     [Google Scholar]
  67. SchmidP. CortesJ. PusztaiL. McArthurH. KümmelS. BerghJ. DenkertC. ParkY.H. HuiR. HarbeckN. TakahashiM. FoukakisT. FaschingP.A. CardosoF. UntchM. JiaL. KarantzaV. ZhaoJ. AktanG. DentR. O’ShaughnessyJ. Pembrolizumab for early triple-negative breast cancer.N. Engl. J. Med.2020382981082110.1056/NEJMoa191054932101663
     [Google Scholar]
  68. ShahA.N. FlaumL. HelenowskiI. Santa-MariaC.A. JainS. RademakerA. NelsonV. TsarwhasD. CristofanilliM. GradisharW. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer.J. Immunother. Cancer202081e00017310.1136/jitc‑2019‑00017332060053
     [Google Scholar]
/content/journals/cgt/10.2174/0115665232283880240301035621
Loading
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Curr. Gene Ther. 25, 72 (2025); https://doi.org/10.2174/0115665232283880240301035621
/content/journals/cgt/10.2174/0115665232283880240301035621
/content/journals/cgt/10.2174/0115665232283880240301035621
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): combined therapy; efficacy; meta-analysis; monotherapy; mTNBC; Pembrolizumab; safety

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test